| A | B | C | D | E | F | G | H | I | J | K | L | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ||||||||||||
| 2 | Name | Indication | MOA | Economics | Price | 30.62 | ||||||
| 3 | DNL310 | MPS II | EDS ERT | Shares | 136.888912 | Q123 | ||||||
| 4 | DNL343 | ALS | eIF2B | MC | 4191.53848544 | |||||||
| 5 | TAK-594/DNL593 | FTD-GRN | Cash | 1288.453 | Q123 | |||||||
| 6 | TNK-920/DNL919 | Alzheimer's | TREM2 | Debt | 0 | Q123 | ||||||
| 7 | DNL126 | Sanfilippo | SGSH ERT | EV | 2903.08548544 | |||||||
| 8 | DNL151/BIIB122 | Parkinson's | ||||||||||
| 9 | DNL788/SAR443820 | CEO: Ryan Watts | ||||||||||
| 10 | DNL758/SAR443122 (eclitasertib) | CLE, UC | RIPK1 | SNY |